{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:28:30Z","timestamp":1791646110227,"version":"4.3.4"},"reference-count":70,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Acalabrutinib, a second\u2010generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off\u2010target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site, ensures potent and sustained blockade of B cell receptor signaling, leading to disruption of key survival and proliferation pathways in malignant B cells. Long\u2010term data from pivotal phase III trials confirmed the high efficacy of acalabrutinib\u2010containing regimens in both treatment\u2010na\u00efve and relapsed\/refractory CLL, showing durable progression\u2010free survival, favorable overall survival rates, and low incidence of serious adverse events such as atrial fibrillation and hypertension, likely attributable to its improved selectivity, with limited immunosuppression and better tolerability leading to lower discontinuation rates compared to first\u2010generation BTKi. Fixed\u2010duration combination with acalabrutinib plus venetoclax, with or without obinutuzumab, has recently emerged as a highly efficacious strategy, providing sustained minimal residual disease (MRD) negativity with manageable toxicity, further supporting the clinical utility of acalabrutinib regimens. The demonstrated efficacy, robust safety, and flexibility of acalabrutinib in both continuous and fixed\u2010duration regimens make it a cornerstone for individualized CLL management, enabling tailored treatment approaches based on patient\u2010 and disease\u2010specific factors.<\/jats:p>","DOI":"10.1111\/ejh.70144","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:29:32Z","timestamp":1773001772000},"page":"759-770","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero\u2010Universitaria Maggiore della Carit\u00e0  Novara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato\u2010Oncology University of Milan \u201cLa Statale\u201d  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687458"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010010"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00857-8"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0463"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.292"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001116"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.084459"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12408"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528019"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111996"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279560"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.02.002"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16020027"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1106579"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13685"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178698"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024476"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278901"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011307"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012142"},{"key":"e_1_2_16_40_1","first-page":"12.18.572223","article-title":"Impact of the Clinically Approved BTK Inhibitors on the Conformation of Full\u2010Length BTK and Analysis of the Development of BTK Resistance Mutations in Chronic Lymphocytic Leukemia","volume":"2023","author":"Joseph R. E.","year":"2024","journal-title":"bioRxiv"},{"issue":"7","key":"e_1_2_16_41_1","first-page":"436","article-title":"Mechanisms of Resistance to BTK Inhibitors in Patients With Chronic Lymphocytic Leukemia","volume":"19","author":"Woyach J. A.","year":"2021","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02662-y"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014206"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2158-0"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107548"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0650"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.74"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800241"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051585"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.07.011"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015132"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009617"},{"key":"e_1_2_16_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00357-5"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.321"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014474"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100543"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2779"},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182974"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007812"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001956"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01192"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101708"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.018"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70144","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:05:15Z","timestamp":1777982715000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ejh.70144"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70144","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"2025-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}